United States v. An Undetermined Quantity of an Article of Drug Labeled as Benylin Cough Syrup

583 F.2d 942, 26 Fed. R. Serv. 2d 196, 1978 U.S. App. LEXIS 9102
CourtCourt of Appeals for the Seventh Circuit
DecidedSeptember 11, 1978
Docket78-1122
StatusPublished
Cited by30 cases

This text of 583 F.2d 942 (United States v. An Undetermined Quantity of an Article of Drug Labeled as Benylin Cough Syrup) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. An Undetermined Quantity of an Article of Drug Labeled as Benylin Cough Syrup, 583 F.2d 942, 26 Fed. R. Serv. 2d 196, 1978 U.S. App. LEXIS 9102 (7th Cir. 1978).

Opinion

PER CURIAM.

This case is one in which both parties appear to have committed misconduct grievous enough under ordinary circumstances to justify judgment for their opponent. In violation of an injunction entered by a federal district judge in Michigan, the Government persisted in an effort under 21 U.S.C. § 334, an in rem proceeding, to condemn $30,000 worth of Benylin Cough Syrup manufactured and owned by appellant Parke, Davis & Company. Although Parke, Davis was given notice of the Government’s action, it declined to appear in the proceedings. During a status call in the condemnation action on April 15, 1977, the district judge ordered the entry of a default judgment against the defendant res. When the district court denied Parke, Davis’ motion to vacate its default judgment, Parke, Davis filed this appeal, raising first the question whether Parke, Davis’ claimed inadvertence or the Government’s apparent misconduct justifies vacating the default, and if so whether the district judge in Michigan had jurisdiction to enter the injunction that the Government violated.

Benylin, a drug for the treatment of congestive symptoms related to colds and allergies, has been marketed as a prescription drug in the United States since 1948. After a series of requests by Parke, Davis for permission to market Benylin over the counter 1 and hints by the Food and Drug Administration (FDA) that the drug’s approval would be withdrawn altogether, in 1973 the FDA deferred any action on Beny-lin pending the report of its Over-The-Counter Drug Advisory Panel on Cold, Cough, Allergy, Bronchodilator and An-tiasthmatic Drugs. In early 1975 that Panel had tentatively concluded that the drug was safe for over-the-counter use. Consequently in response to a Parke, Davis letter inquiring about going ahead with over-the-counter sales, an FDA attorney informed Parke, Davis that in view of the Panel’s apparent decision “there would be almost no possibility that we would institute legal action at this time.” The FDA letter added that if Benylin were to be marketed at that time, Parke, Davis would assume the risk that the Agency might not accept the Panel’s finding.

Parke, Davis commenced marketing Be-nylin Cough Syrup without a prescription warning in September 1975. Shortly there *945 after, the FDA announced its policy in cases in which a manufacturer commenced over-the-counter distribution of a drug before a final FDA monograph on the safety of that drug became effective. The Commissioner of the FDA advised that if he expresses tentative disagreement with a panel recommendation, the agency will act immediately to restrain the over-the-counter distribution of the product and will not await publication of a final monograph. See 41 Fed.Reg. 32580. A month after that regulation was published and a year after Parke, Davis began marketing Benylin over the counter, the Panel report recommending a safe and effective classification for the drug was published in the Federal Register. 41 Fed. Reg. 38312. In the preamble to that proposed monograph, however, the Commissioner stated that he was deferring decision on the Panel’s recommendation as to Beny-lin. After some inquiry into a supplemental new drug application for Benylin filed by Parke, Davis, the FDA announced that Benylin would be subject to immediate enforcement actions. 41 Fed.Reg. 52536. On November 24, 1976, the FDA sent a telegram to Parke, Davis requesting that the Company recall all existing stocks of Beny-lin Cough Syrup that did not contain the required prescription labeling.

Responding to this shift in its fortunes, Parke, Davis filed a complaint on November 29, 1976, in the United States District Court for the Eastern District of Michigan seeking a declaration that the FDA’s order regarding enforcement actions was arbitrary, capricious and an abuse of discretion. Also requested were a preliminary injunction and a permanent injunction prohibiting the FDA from initiating enforcement actions pursuant to the Agency’s order until the FDA’s administrative proceedings were completed.

The Michigan District Court scheduled a hearing on the requested preliminary injunction on December 3. Meanwhile, on November 30, the United States took action in the Northern District of Illinois against the res involved in this proceeding. It filed a verified complaint for condemnation and forfeiture under 21 U.S.C. § 334. A warrant of seizure and monition was issued by the district court on the same date and the United States Marshal thereupon executed the warrant by seizure of the drugs named as defendant. The complaint and warrant of seizure and monition were personally served on a Parke, Davis district manager, in whose possession the seized drugs were found. Notice of the seizure was published and mailed to Parke, Davis.

After holding its scheduled hearing and finding that the FDA’s enforcement action was arbitrary and capricious and that Parke, Davis was threatened with irreparable harm, the Michigan district judge entered a two-part preliminary injunction on December 8, 1976. First he ordered that the FDA defendants, “their agents, including the United States of America, and defendant’s servants, employees, and attorneys, and all persons in active concert and participation with them,” are restrained from instituting enforcement actions until final agency action on Parke, Davis’ supplemental application. This part of the injunction did not affect the Illinois proceedings because those enforcement proceedings already had been instituted when the preliminary injunction was entered. The Michigan court also ordered that the same parties take “immediate steps to cause the release of the Benylin Cough Syrup seized since the commencement of this action on November 29, 1976.” Although the United States Attorney’s office in the Northern District of Illinois was aware of the Michigan court’s injunction (see U.S.Supp.Br. App. A), it made no effort to comply and no steps were taken to release the seized Benylin.

Assertedly believing that the Illinois case was being held in abeyance pending the appeal of the Michigan injunction, Parke, Kavis did not file a claim for the Benylin seized in the Northern District of Illinois. 2 On his own motion, the district judge scheduled and held status calls in this case on *946 March 18, 1977, and on April 15, 1977. The United States Attorney appeared on both occasions, but apparently since it had not filed a claim, Parke, Davis received no notice and did not appear on either occasion. For unexplained reasons, the Assistant United States Attorney handling the case did not extend Parke, Davis the courtesy of informal notice of the status calls. At the first status call, the Assistant United States Attorney advised the district court of the Michigan injunction. At the second status call the district court ordered the entry of default against the defendant res. It later also ordered the entry of a decree of condemnation and order of destruction. When Parke, Davis learned of the default, it filed a “special appearance” and moved to set aside the judgment and to stay the proceedings. After five and one-half months the district judge denied the motion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Christiansen v. Adams
251 F.R.D. 358 (S.D. Illinois, 2008)
In Re: Estate of James H. Williams
Court of Appeals of Tennessee, 2003
Travelodge Hotels, Inc. v. Taurus Hotels Corp.
179 F.R.D. 569 (C.D. Illinois, 1998)
Win-Tex Products, Inc. v. United States
17 Ct. Int'l Trade 786 (Court of International Trade, 1993)
Aggie Investments GP v. Public Service Commission
470 N.W.2d 805 (North Dakota Supreme Court, 1991)
Simon v. Pay Tel Management, Inc.
782 F. Supp. 1219 (N.D. Illinois, 1991)
Pelican Production Corp. v. Marino
893 F.2d 1143 (Tenth Circuit, 1990)
Mahaffey & Gore, P.C. v. Crist (In Re Crist)
99 B.R. 878 (N.D. Illinois, 1989)
Marx v. Government of Guam
866 F.2d 294 (Ninth Circuit, 1989)
Diane Passarella v. Hilton International Co.
810 F.2d 674 (Seventh Circuit, 1987)
Allen Russell Publishing, Inc. v. Levy
109 F.R.D. 315 (N.D. Illinois, 1985)
United States v. Board of Educ. of City of Chicago
588 F. Supp. 132 (N.D. Illinois, 1984)
Rodriguez v. Marks Bros. Pickle Co.
102 F.R.D. 104 (E.D. Wisconsin, 1984)

Cite This Page — Counsel Stack

Bluebook (online)
583 F.2d 942, 26 Fed. R. Serv. 2d 196, 1978 U.S. App. LEXIS 9102, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-an-undetermined-quantity-of-an-article-of-drug-labeled-as-ca7-1978.